Good to see this agreement in place In this region, the...

Good to see this agreement in place

In this region, the prevalence of bacterial vaginosis among a female population of 238 million is 25% (59.5 million potential users)

The numbers are huge. Just imagine if we managed to capture 10% of this cohort (6 million females)

Good to see the branding is to be VivaGel^® BV  and not Betadine BV (MUNDIPHARMA)

The initial licensee deal is for United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, Jordan, Lebanon, Egypt, Libya, Morocco, Tunisia, and Algeria. (13 countries), but does not include the highlighted countries in yellow below

The MENA REGION COVERS 20 countries. Starpharma has registration in the Mena Region

Algeria, Bahrain, Egypt, Iraq, Iran, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen

So we are now coming to the end of February. The transference process for the existing VivaGel® BV registrations and phasing in of the product into these jurisdictions will begin in FY 2025. Remember it takes time.

If there was an upfront fee for this licensing deal it would have been announced.

Starpharma is responsible with supplying product to ITROM.
ITROM are responsible for sales, distribution and marketing in the MENA (Middle East North Africa) region


One license deal out of the way
Multiple ones to come